Bragar Eagel & Squire, P.C. is Investigating Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on behalf of Adamas stockholders. Our investigation concerns whether Adamas has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
In January 2018, Adamas completed its Second Public Offering (“SPO”), issuing approximately 3 million shares of common stock priced at $41.50 per share. According to a recently filed complaint, before launching Gocovri, a medicine for treating dyskinesia in Parkinson’s disease patients treated with levodopa therapy, Adamas knew it faced significant roadblocks that would dramatically reduce its ability to sell the drug, yet did not inform — and actively misled — the market about this problem.
In October 2018, Merrill Lynch released a study which cast serious doubt on Gocovri’s ability to achieve a sizeable market share and emphasized that Adamas failed to include critical information.
In March 2019, Adamas backtracked on prior issued growth estimates and no longer made predictions regarding Gocovri’s ability to achieve a sizeable market share.
Since the SPO, Adamas stock has declined significantly. As of market close on May 28, 2019, the stock price was $4.80.
If you purchased or otherwise acquired Adamas shares pursuant and/or traceable to the SPO and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Adamas please go to http://www.bespc.com/adms/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.